Text: H.R.4667 — 116th Congress (2019-2020)All Information (Except Text)

There is one version of the bill.

Text available as:

Shown Here:
Introduced in House (10/11/2019)


116th CONGRESS
1st Session
H. R. 4667


To amend the 21st Century Cures Act to reauthorize funding for NIH innovation projects, and for other purposes.


IN THE HOUSE OF REPRESENTATIVES

October 11, 2019

Ms. Sherrill (for herself, Mr. Levin of California, and Ms. Spanberger) introduced the following bill; which was referred to the Committee on Energy and Commerce


A BILL

To amend the 21st Century Cures Act to reauthorize funding for NIH innovation projects, and for other purposes.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. Short title.

This Act may be cited as the “Biomedical Innovation Expansion Act of 2019”.

SEC. 2. Reauthorization of NIH innovation proj­ects.

(a) Transfers.—Section 1001(b)(2)(A) of the 21st Century Cures Act (Public Law 114–255) is amended by striking clauses (v) through (x) and inserting the following:

“(v) For fiscal year 2021, $854,000,000.

“(vi) For fiscal year 2022, $1,051,000,000.

“(vii) For fiscal year 2023, $1,345,000,000.

“(viii) For fiscal year 2024, $1,271,000,000.

“(ix) For fiscal year 2025, $1,301,000,000.

“(x) For fiscal year 2026, $1,306,000,000.

“(xi) For fiscal year 2027, $1,336,000,000.

“(xii) For fiscal year 2028, $1,376,000,000.

“(xiii) For fiscal year 2029, $1,436,000,000.

“(xiv) For fiscal year 2030, $1,469,000,000.”.

(b) Authorization of appropriations.—Section 1001(b)(3)(A) of the 21st Century Cures Act (Public Law 114–255) is amended by striking “2026” and inserting “2030”.

(c) Offsetting future appropriations.—Section 1001(b)(3)(B) of the 21st Century Cures Act (Public Law 114–255) is amended by striking “2026” and inserting “2030”.

(d) NIH innovation projects.—Section 1001(b)(4) of the 21st Century Cures Act (Public Law 114–255) is amended—

(1) in the matter preceding subparagraph (A), by striking “2026” and inserting “2030”;

(2) in subparagraph (A)—

(A) in the matter preceding clause (i), by striking “$1,455,000,000” and inserting “$4,413,000,000”; and

(B) by striking clauses (v) through (x) and inserting the following:

“(v) For fiscal year 2021, $209,000,000.

“(vi) For fiscal year 2022, $300,000,000.

“(vii) For fiscal year 2023, $419,000,000.

“(viii) For each fiscal years 2024 through 2030, $430,000,000.”;

(3) in subparagraph (B)—

(A) in the matter preceding clause (i), by striking “$1,511,000,000” and inserting “$4,428,000,000”; and

(B) by striking clauses (v) through (x) and inserting the following:

“(v) For fiscal year 2021, $250,000,000.

“(vi) For fiscal year 2022, $302,000,000.

“(vii) For fiscal year 2023, $450,000,000.

“(viii) For each of fiscal years 2024, 2025, and 2026, $400,000,000.

“(ix) For fiscal year 2027, $425,000,000.

“(x) For fiscal years 2028, $450,000,000.

“(xi) For each of fiscal years 2029 and 2030, $500,000,000.”;

(4) in subparagraph (C)—

(A) in the matter preceding clause (i), by striking “$1,800,000,000” and inserting “$3,312,000,000”; and

(B) by amending clause (vii) to read as follows:

“(vii) For each of fiscal years 2023 through 2030, $216,000,000.”;

(5) in subparagraph (D)—

(A) in the matter preceding clause (i), by striking “$30,000,000” and inserting “$250,000,000”; and

(B) by striking clause (iv) and inserting the following:

“(iv) For each of fiscal years 2021, 2022, and 2023, $50,000,000.

“(v) For each of fiscal years 2024 through 2030, $10,000,000.”; and

(6) by adding at the end the following:

“(E) To support research related to combating antimicrobial resistance and antibiotic resistant bacteria, not to exceed a total of $1,635,000,000, as follows:

“(i) For fiscal year 2021, $100,000,000.

“(ii) For each of fiscal years 2022 through 2024, $150,000,000.

“(iii) For each of fiscal years 2025 through 2027, $175,000,000.

“(iv) For each of fiscal years 2028 and 2029, $180,000,000.

“(v) For fiscal year 2030, $200,000,000.

“(F) To support research and research activities related to rare diseases or conditions, not to exceed a total of $758,000,000, as follows:

“(i) For fiscal year 2021, $50,000,000.

“(ii) For fiscal year 2022, $55,000,000.

“(iii) For fiscal year 2023, $60,000,000.

“(iv) For fiscal year 2024, $65,000,000.

“(v) For fiscal year 2025, $70,000,000.

“(vi) For fiscal year 2026, $75,000,000.

“(vii) For fiscal year 2027, $80,000,000.

“(viii) For fiscal year 2028, $90,000,000.

“(ix) For fiscal year 2029, $100,000,000.

“(x) For fiscal year 2030, $113,000,000.”.

(e) Workplan.—Section 1001(c)(1)(A) of the 21st Century Cures Act (Public Law 114–255) is amended by striking “2026” and inserting “2030”.

(f) Recommendations.—Section 1001(c)(1)(C)(i) of the 21st Century Cures Act (Public Law 114–255) is amended by striking “2026” and inserting “2030”.

(g) Annual reports.—Section 1001(c)(2)(A) of the 21st Century Cures Act (Public Law 114–255) is amended by striking “2027” and inserting “2030”.

(h) Sunset.—Section 1001(e) of the 21st Century Cures Act (Public Law 114–255) is amended by striking “September 30, 2026” and inserting “September 30, 2030”.


Share This